ArthNow Logo
ArthNow
•3 min read•
✦Reported by Financial Express

Apollo Hospitals Hits Record, Max Health Jumps 4% on Macquarie's Double Upgrades

Apollo Hospitals Hits Record, Max Health Jumps 4% on Macquarie's Double Upgrades
Source: Financial Express

Executive Brief • Key Highlights

Fast factual intelligence distilled for busy investors, executives, and answer bots:

  • ✓Apollo Hospitals and Max Healthcare shares rallied after Macquarie upgraded both stocks.
  • ✓Apollo hit a record high of Rs 9,205, while Max jumped 4% to Rs 1,090.
  • ✓Macquarie said, "Newly commissioned facilities utilisation has been strong," which should help growth.

Story at a Glance

Category
Indian Markets
Reported By
Financial Express
Reading Speed
3 Minute(s)
Market Focus
India Economy

Apollo Hospitals and Max Healthcare rally after Macquarie upgrades both stocks, seeing up to 34% upside.

The Apollo Hospitals share price skyrocketed to a fresh record high of Rs 9,205 apiece, up over 5% from the previous close, while Max Healthcare share price soared over 4% to a three-month high of Rs 1,090 apiece.

Double upgrades for two hospital stocks

Global brokerage Macquarie double upgraded both the stocks to 'Outperform' from 'Underperform' as it believes consensus earnings have bottomed out for the sector and valuations have cooled down.

The brokerage raised its target price on Apollo Hospital to Rs 10,500, implying an upside of around 15% from the current price of Rs 9,168 apiece. It raised the price target on Max to Rs 1,450 apiece, which reflects an upside of 34% from the current price of Rs 1,081.50 apiece.

🔒
Premium Content

Unlock the Full Story with ArthNow Premium

To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.

✓ Full Unabridged Reports✓ Executive Audio Briefs✓ 100% Ad-Free Reading
Verified Publication Source

Financial Express

Read the full, original unfiltered story directly on the publisher's portal.

Visit Original Article

This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.